| Application number | Title of the application | Filing Date | Status |
|---|
Array
(
[id] => 432036
[patent_doc_number] => 07264809
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2007-09-04
[patent_title] => 'Methods of inhibiting platelet activation and recruitment'
[patent_app_type] => utility
[patent_app_number] => 09/807660
[patent_app_country] => US
[patent_app_date] => 1999-10-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 45
[patent_no_of_words] => 25600
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 74
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/264/07264809.pdf
[firstpage_image] =>[orig_patent_app_number] => 09807660
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/807660 | Methods of inhibiting platelet activation and recruitment | Oct 12, 1999 | Issued |
| 09/410963 | RECOMBINANT CAT ALLERGEN, FEL DI, EXPRESSED IN BACULOVIRUS FOR DIAGNOSIS AND TREATMENT OF CAT ALLERGY | Oct 4, 1999 | Abandoned |
Array
(
[id] => 996310
[patent_doc_number] => 06913749
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2005-07-05
[patent_title] => 'Immunogenic polypeptides for inducing anti-self IgE responses'
[patent_app_type] => utility
[patent_app_number] => 09/401636
[patent_app_country] => US
[patent_app_date] => 1999-09-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 10933
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/913/06913749.pdf
[firstpage_image] =>[orig_patent_app_number] => 09401636
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/401636 | Immunogenic polypeptides for inducing anti-self IgE responses | Sep 21, 1999 | Issued |
| 09/400814 | SAFETY INJECTION DEVICE | Sep 21, 1999 | Abandoned |
| 09/397198 | METHODS OF TREATING IGE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN | Sep 15, 1999 | Abandoned |
Array
(
[id] => 1499986
[patent_doc_number] => 06485955
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2002-11-26
[patent_title] => 'Quiescent cell dipeptidyl peptidase: a novel cytoplasmic serine protease'
[patent_app_type] => B1
[patent_app_number] => 09/388413
[patent_app_country] => US
[patent_app_date] => 1999-09-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 7066
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/485/06485955.pdf
[firstpage_image] =>[orig_patent_app_number] => 09388413
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/388413 | Quiescent cell dipeptidyl peptidase: a novel cytoplasmic serine protease | Aug 31, 1999 | Issued |
Array
(
[id] => 1470653
[patent_doc_number] => 06407215
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2002-06-18
[patent_title] => 'Antibodies to Mch2, an apoptotic cysteine protease'
[patent_app_type] => B1
[patent_app_number] => 09/376156
[patent_app_country] => US
[patent_app_date] => 1999-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9925
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/407/06407215.pdf
[firstpage_image] =>[orig_patent_app_number] => 09376156
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/376156 | Antibodies to Mch2, an apoptotic cysteine protease | Aug 16, 1999 | Issued |
Array
(
[id] => 1321888
[patent_doc_number] => 06602509
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2003-08-05
[patent_title] => 'Compound and method for the prevention and/or the treatment of allergy'
[patent_app_type] => B1
[patent_app_number] => 09/362731
[patent_app_country] => US
[patent_app_date] => 1999-07-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 8457
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/602/06602509.pdf
[firstpage_image] =>[orig_patent_app_number] => 09362731
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/362731 | Compound and method for the prevention and/or the treatment of allergy | Jul 28, 1999 | Issued |
| 09/360004 | CATHETER DEVICE HAVING MULTI-LUMEN REINFORCED SHAFT AND METHOD OF MANUFACTURE FOR SAME | Jul 22, 1999 | Abandoned |
Array
(
[id] => 1331179
[patent_doc_number] => 06596473
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2003-07-22
[patent_title] => 'Active survival domains of IGF-IR and methods of use'
[patent_app_type] => B1
[patent_app_number] => 09/343551
[patent_app_country] => US
[patent_app_date] => 1999-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 46
[patent_no_of_words] => 23009
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 116
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/596/06596473.pdf
[firstpage_image] =>[orig_patent_app_number] => 09343551
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/343551 | Active survival domains of IGF-IR and methods of use | Jun 29, 1999 | Issued |
| 09/343406 | ANTIGEN-SPECIFIC, ACTIVATED T-LYMPHOCYTES, DETECTION AND USE | Jun 29, 1999 | Abandoned |
Array
(
[id] => 1240664
[patent_doc_number] => 06686450
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2004-02-03
[patent_title] => 'Immunosuppressive agents that inhibit calcineurin function and uses of these agents'
[patent_app_type] => B1
[patent_app_number] => 09/335011
[patent_app_country] => US
[patent_app_date] => 1999-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 40
[patent_figures_cnt] => 47
[patent_no_of_words] => 17880
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/06/686/06686450.pdf
[firstpage_image] =>[orig_patent_app_number] => 09335011
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/335011 | Immunosuppressive agents that inhibit calcineurin function and uses of these agents | Jun 16, 1999 | Issued |
| 09/335318 | POLYNUCLEOTIDES ENCODING UROGENITAL SINUS DERIVED GROWTH INHIBITORY FACTOR AND VECTORS | Jun 16, 1999 | Abandoned |
| 09/242198 | METHOD FOR DETERMINING EXPRESSION OF ABERRANT FORMS OF APC PROTEIN | Jun 13, 1999 | Abandoned |
Array
(
[id] => 232465
[patent_doc_number] => 07597889
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2009-10-06
[patent_title] => 'Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis'
[patent_app_type] => utility
[patent_app_number] => 09/674857
[patent_app_country] => US
[patent_app_date] => 1999-05-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 22
[patent_no_of_words] => 15783
[patent_no_of_claims] => 52
[patent_no_of_ind_claims] => 9
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/597/07597889.pdf
[firstpage_image] =>[orig_patent_app_number] => 09674857
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/674857 | Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis | May 6, 1999 | Issued |
Array
(
[id] => 765319
[patent_doc_number] => 07008623
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2006-03-07
[patent_title] => 'Antibodies to CD23, derivatives thereof, and their therapeutic uses'
[patent_app_type] => utility
[patent_app_number] => 09/674716
[patent_app_country] => US
[patent_app_date] => 1999-05-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 12965
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/008/07008623.pdf
[firstpage_image] =>[orig_patent_app_number] => 09674716
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/674716 | Antibodies to CD23, derivatives thereof, and their therapeutic uses | May 6, 1999 | Issued |
Array
(
[id] => 735917
[patent_doc_number] => 07033589
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2006-04-25
[patent_title] => 'γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics'
[patent_app_type] => utility
[patent_app_number] => 09/292053
[patent_app_country] => US
[patent_app_date] => 1999-04-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 20271
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 181
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/033/07033589.pdf
[firstpage_image] =>[orig_patent_app_number] => 09292053
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/292053 | γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics | Apr 13, 1999 | Issued |
Array
(
[id] => 5967378
[patent_doc_number] => 20020090381
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2002-07-11
[patent_title] => 'SYSTEM FOR CONTROLLING IMMUNE SYSTEM RESPONSE TO ANTIGEN'
[patent_app_type] => new
[patent_app_number] => 09/290029
[patent_app_country] => US
[patent_app_date] => 1999-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13111
[patent_no_of_claims] => 281
[patent_no_of_ind_claims] => 22
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0090/20020090381.pdf
[firstpage_image] =>[orig_patent_app_number] => 09290029
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/290029 | SYSTEM FOR CONTROLLING IMMUNE SYSTEM RESPONSE TO ANTIGEN | Apr 8, 1999 | Abandoned |
Array
(
[id] => 723944
[patent_doc_number] => 07045305
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2006-05-16
[patent_title] => 'Methods and reagents for targeting organic compounds to selected cellular locations'
[patent_app_type] => utility
[patent_app_number] => 09/403882
[patent_app_country] => US
[patent_app_date] => 1999-04-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 17030
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 120
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/045/07045305.pdf
[firstpage_image] =>[orig_patent_app_number] => 09403882
[rel_patent_id] =>[rel_patent_doc_number] =>) 09/403882 | Methods and reagents for targeting organic compounds to selected cellular locations | Apr 7, 1999 | Issued |
| 09/214913 | CONJUGATES OF SOLUBLE PEPTIDIC COMPOUNDS WITH MEMBRANE-BINDING AGENTS | Mar 15, 1999 | Abandoned |
